Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 116

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 116
---
 or liability which are not included in, or in greater scope than, Yissum’s
obligations or liabilities under the license agreement; or (b) require the sublicensee to enter into a new license agreement on substantially
the same terms and conditions as those contained in the license agreement.

<div align='center'>74</div>

We have the first right to prepare, file, prosecute
and maintain any patent applications and patents in respect of the licensed technology and any part thereof, at our expense, subject
to certain conditions. We are required to file each licensed patent application at least in the United States, Europe and Japan. We are
also required to take action, in reasonable commercial circumstances and after consultation with patent counsel, in the prosecution,
prevention or termination of any infringement of patents licensed under the agreement. We are responsible for the expenses of any patent
infringement suit that we bring, including the expenses incurred by Yissum in connection with such suits. We are entitled to reimbursement
from any awards or settlements recovered in such suit or in the settlement thereof for all costs and expenses involved in the prosecution
of any such suit. If we elect not to pursue any action in connection with infringement and Yissum in good faith disagrees with us that
it is in the mutual best interest of both parties not to pursue any such action, then, at our election, we may either allow Yissum to
pursue such actions, at Yissum’s expense, or pay Yissum the royalties that Yissum would otherwise receive from us attributable
to lost sales resulting from such alleged infringement

Research and Option Agreement with Yissum for the ARB Blockers

On October 25, 2023, we entered into Research
and Option Agreement with Yissum with respect to the nanoparticles-based formulation of angiotensin receptor blockers (ARB) for intravenous
administration. Under the agreement, we shall provide funding for research and development studies to be performed by researchers at
Hebrew University related to the formulation, preparation and characterization of nanoparticles-based formulation of angiotensin receptor
blockers (ARB) for intravenous administration. In consideration for the research services, we agreed to pay research service fees of
$150,000, in periodic payments subject to completing specified milestones. All data generated from the provision of the services, including
any reports, which are specifically required and contemplated under such agreement, shall be owned by us upon full payment of the research
services fees.